L-ELISA of human aggregate agent (PG) quantifies the Hu aggregate agent (PG) in synovial fluid, serum, plasma, buffered solution or human cell culture medium. The dosage will recognize only natural human aggregatecan (PG) and...
L-ELISA of human aggregate agent (PG) quantifies the Hu aggregate agent (PG) in synovial fluid, serum, plasma, buffered solution or human cell culture medium. The dosage will recognize only natural and recombinant human aggregate agent (PG). Principle of the L-ELISA (immuno-enzymatic test) solid phase sandwich of human aggrecan (PG) is designed to measure the amount of the target bound between a pair of matched antibodies. A target-specific antibody was pre-vested in the wells of the supplied microplate. Samples, standards or controls are then added to these wells and bound to immobilized antibody (capture). The sandwich is formed by adding the second enzyme-conjugated antibody (detector), binding to the target on a different epitope from the capture antibody. After incubation and washing steps to remove the microplate from the non-bonded substances, a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this coloured product is directly proportional to the concentration of TP (p) present in the original sample. Rigorous validation Each batch manufactured from this ELISA kit is tested for quality for criteria such as sensitivity, specificity, accuracy and batch-to-batch consistency. See the product manual for more information on validation.
L-Aggrecan, also known as cartilage specific protein glycane (CSPCP) or chondroitin sulfate protein 1-ACAN-encoded protein, is a protein that is used to control the protein. The coded protein is an integral part of the extracellular matrix in cartilaginous tissue and resists compression in cartilage. The human form of the protein consists of 2316 large amino acids (-250 kDa) and can be expressed in several isoforms due to its alternative splicing. L-Aggrecan has a pin structure on which the chondroitin sulphate and keratane sulphate chains are attached to an expanded protein nucleus. The synthesis and degradation of the aggrecan is studied to determine their role in cartilage deterioration in joint lesions, disease and aging. It contains three interglobulary domains (IGD), G1, G2 and G3 involved in aggregation, binding of l-hyaluronane, cell adhesion, and chondrocyte apoptosis. The joint cartilage fragments of the dagrecane release into the synovial fluid at all stages of human osteoarthritis following cleavage caused by the activity of l'aggrecanase and MMP. The BC-3 and BC-4 antibodies can be used to detect these new d-aggrecanase epitopes (ARGSVXXX) and MMP (XXXVDIPEN), respectively. Order information
Shipping conditions : dry ice
Sensitivity
Sensitivity of the dosage: 0.9 ng.
Measurement range
Dose range: 10-250 ng/ml.
Duration of dosing
Total duration of dosing: 3 h 15 min.
Reproducibility
Coefficient of intra-dose variation 2.1%, inter-dose 5.6%.
Technical specifications
| General |
| Brand | Invitrogen |
| Supplier ref. (Fisher Scientific) | 10384353 |
| Specifications |
| Accession number | P16112 |
| Dose range | 10-250 ng/ml |
| Sensitivity of the dosage | 0.9 ng |
| Conjugate | HRP |
| Product type | Kit ELISA |
| Type of sample | Synovial liquid, Serum, Surnatant |
| Target species | Human |
| For use with (application) | Colorimetric detection |
| For use with (equipment) | Colorimetric microplate reader |
| Genetic identification (Enter) | 176 |
| Gene symbol(s) | AGC1,AGCAN,CSPG1,CSPGCP,MSK16,SEDK |
| Incubation time | 3.25 h |
| Coefficient of inter-dose variation | 5.6% |
| Coefficient of intra-dose variation | 2.1% |
| Contents of kits | 96-well pre-coated plate, Standard, Sample diluent, Incubation buffer, HRP conjugate antibody, Conjugate diluent, Wash pad, Chromogen, Stop solution, isotypic |
| Marker or dye | HRP |
| Genetic marker | PG |
| Quantity | 96 tests |
| Regulatory status | RUO |
| Target | Human |
| Test time | 1 h 20 min |
| Physical characteristics |
| Volume of sample | Serum, 20 μl; supernatant, 10 μl; synovial liquid, 25 μl |
| Storage and shipping |
| Storage conditions | 2°C to 8°C |
| Total duration of dosing | 3 h 15 min |
Origin and customs
| Manufacturer ref. | KAP1461 |
|---|
| Country of origin | United Kingdom |
|---|
| HS customs code | 3002 15 00 00 |
|---|
A question or a specific configuration?
Contact us for a quote.